Tivic Health Systems, Inc. (TIVC)

Tivic Health Systems, Inc. (TIVC) stock has experienced a substantial decline of 78.63% over the past year. Key events impacting the stock include the strategic transformation into an immunotherapy company, which led to a significant widening of its net loss for the full year 2025, and facing a Nasdaq minimum bid price deficiency and delisting risk in March 2026. A director added 19,000 shares in an open-market buy in April 2026, and insider buying has exceeded selling in the past three months. The company secured a non-clinical evaluation agreement for Entolimod with NIAID in March 2026 and received a formal request for information from the Ukrainian Ministry of Health regarding strategic stockpiling of Entolimod. Tivic also reported having $12.6 million in cash and cash equivalents at December 31, 2025.

With Tivic Health Systems's strategic pivot, the demand seasonality for its products and services has significantly changed. The company has discontinued its consumer product business, and its current focus is on its biopharma program and its CDMO services through Velocity Bioworks. Demand for these types of biopharmaceutical products and contract manufacturing services is generally not subject to the same seasonal fluctuations as consumer health devices.

Tivic Health Systems, Inc. is a diversified immunotherapeutics and health technology company focused on harnessing the body's biopharmaceutical and bioelectronic systems to target the immune system and address unmet medical needs. The company's biologics platform centers on Entolimod™, a novel Toll-like Receptor 5 (TLR5) agonist, in late-stage development for acute radiation syndrome (ARS) and also being developed for neutropenia and lymphocyte exhaustion. Tivic Health has also expanded into contract development and manufacturing organization (CDMO) services through its wholly-owned subsidiary, Velocity Bioworks™.

Tivic Health Systems, Inc. is headquartered in Fremont, California, United States, while its subsidiary, Velocity Bioworks, is based in San Antonio, Texas. The company previously sold its ClearUP products through direct-to-consumer channels and to U.S. online retailers. With the strategic pivot to biotherapeutics and CDMO services, the geographic focus primarily involves the U.S. for development and potential government contracts, with the intent of selling biologic compounds either inside or outside the United States.

Tivic Health Systems's brand reputation has been shaped by its significant strategic pivot and ongoing financial challenges. The company has actively communicated its transformation into a focused immunotherapy company, emphasizing its lead drug candidate Entolimod and the establishment of Velocity Bioworks. However, the company's reputation has also been affected by negative financial news, including a significant widening of its net loss, substantial revenue decline, and facing a Nasdaq minimum bid price deficiency and delisting risk.

Tivic Health Systems, Inc. has 9 institutional owners and shareholders who have filed 13D/G or 13F forms, holding a total of 183,553 shares. Individual insiders own a significant portion of the company, with John Claude being the largest individual shareholder, owning 1.20 million shares, representing 67.73% of the company. Overall, Tivic Health Systems is owned by 4.64% institutional shareholders, 84.72% Tivic Health Systems insiders, and 10.64% retail investors.